Emergency BU Alert Boston University's Charles River and Medical Center Campuses will be closing today, Monday, January 26, 2015 at 5:00 PM and will be closed all day Tuesday, January 27, 2015. All normal academic and administrative activities (e.g. classes, seminars and meetings) that are scheduled to take place after 5:00 PM on Monday are cancelled. When classes resume, they will resume on the regular class schedule. Whether or how classes are to be made up is at the discretion of the faculty member. For detailed information about the Boston University Medical campus, please go to http://www.bu.edu/ehs/comm Please note: Employees in essential services must report as scheduled. Essential services include, but are not limited to, University Police, Public Safety, Emergency Patient Treatment, Facilities Management and Planning, Environmental Health & Safety, University Dining Services, Mail Services, Student Health Services and the University Switchboard. For the very latest information, please go to http://www.bu.edu/today

Tamar Aprahamian, PhD













Assistant Professor


B.S. - Boston College
Ph.D. - Tufts University

General field of research:

Autoimmunity; Cardiovascular Disease

Contact information:

Phone: (617)-414 3368



SLE; Autoimmunity; Atherosclerosis; Mouse models

Summary of research interest:

My research focuses on the interactions between systemic lupus erythematosus (SLE) and accelerated atherosclerosis. Several lines of evidence suggest that impaired apoptotic cell clearance and dysregulated inflammation play a role in the development and progression of both disease processes. Peroxisome proliferator-activated receptor gamma (PPARg) agonists exert a variety of immunomodulatory effects including the production of adiponectin, an anti-inflammatory cytokine produced by adipocytes which has also recently been shown to mediate the clearance of apoptotic material. We have shown that this induction of adiponectin results in beneficial effects on disease. We are currently using several mouse genetic models to examine the signaling mechanisms by which these drugs exert their beneficial effects through the adiponectin pathway.

Stemming from our studies on adiponectin, a recent exploration in the lab has been to elucidate how angiogenic factor expression in adipose tissue affects not only vascularity, but also tissue function, and the potential effects on cardiovascular complications of obesity.

Selected publications:

Richez, C, Richards, R, Duffau, P, Weitzner, Z, Andry, CD, Rifkin, IR, Aprahamian, T. (2013) The Effect of Mycophenolate Mofetil on Disease Development in the gld.apoE-/- Mouse Model of Premature Atherosclerosis and Systemic Lupus Erythematosus. PLOS One. 8(4):e61042.

Aprahamian, T., (2013) Elevated adiponectin expression promotes adipose tissue vascularity under conditions of diet-induced obesity. Metabolism Dec;62(12):1730-8.

Aprahamian, T., Bonegio, RG, Weitzner, Z, Rifkin, IR. (2014) PPARγ Agonists in the Prevention and Treatment of Murine Systemic Lupus Erythematosus. Immunology. 2014 Jul;142(3):363-73.

Aprahamian, T., Sam F. Adiponectin in cardiovascular inflammation and obesity. Int J Inflam. 2011;2011:376909.

Parker J, Menn-Josephy H, Laskow B, Takemura Y, Aprahamian T. Modulation of lupus phenotype by adiponectin deficiency in autoimmune mouse models.  J Clin Immunol. 2011 Apr;31(2):167-73.

Richez, C., Yasuda, K., Bonegio, RG., Watkins, AA., Aprahamian, T., Busto, P., Richard,s RJ., Liu, CL., Cheung, R., Utz, PJ., Marshak-Rothstein, A., Rifkin, IR. IFN regulatory factor 5 is required for disease development in the FcgammaRIIB-/-Yaa and FcgammaRIIB-/- mouse models of systemic lupus erythematosus. Journal of Immunology. 2010 Jan 15;184(2):796-806.

Aprahamian, T., Bonegio, RG., Richez, C., Yasuda, K., Chiang, L-K, Sato, K., Walsh, K., Rifkin, I. (2009) The Peroxisome Proliferator-Activated Receptor Gamma Agonist Rosiglitazone Ameliorates Murine Lupus By Induction Of Adiponectin. Journal of Immunology. Jan 1; 182(1):340-6.

Aprahamian, T., Takemura, Y., Goukassian, D., Walsh, K. (2008) Aging is associated with decline in clearance of apoptotic cells. Clinical and Experimental Immunology. Jun;152(3):448-55.

Takemura, Y., Ouchi, N., Shibata, R., Aprahamian, T., Kirber, M.T., Summer, R.S., Kihara, S., Walsh, K. (2007) Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J. Clin. Invest. Feb 1;117(2):375-386.

Aprahamian, T., Bonegio, R., Rizzo, J., Perlman, H., Lefer, D.J., Rifkin, I., Walsh, K. (2006). Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. J Immunol. Sep 1;177(5):3028-34.

Aprahamian, T., Rifkin, I., Bonegio, R., Hugel, B., Freyssinet, J.M., Sato, K., Castellot, J.J. Jr, Walsh, K. (2004) Impaired clearance of apoptotic cells promotes synergy between atherogenesis and autoimmune disease. J Exp Med 199:1121-1131.